PDF herunterladen
Neuropediatrics 2025; 56(02): 102-110
DOI: 10.1055/a-2517-7800
Original Article

Adrenocorticotropic Hormone versus Prednisolone for Infantile Epileptic Spasms Syndrome: A Systematic Review and Economic Evaluation

Ruonan Gao 
1   Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China
2   NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
4   West China School of Medicine, Sichuan University, Chengdu, China
,
Xiao Cheng
1   Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China
2   NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
,
Liang Huang 
1   Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China
2   NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
,
Rong Luo
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
5   Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China
,
Linan Zeng
1   Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China
2   NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
,
Guo Cheng
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
5   Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China
6   Laboratory of Molecular Translational Medicine, Center for Translational Medicine, Sichuan University, Chengdu, China
,
Qin Yu
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
7   National Drug Clinical Trial Institute, West China Second University Hospital, Sichuan University, Chengdu, China
,
Hailong Li
1   Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China
2   NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
,
Lingli Zhang
1   Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China
2   NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China
3   Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
8   Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
› Institutsangaben Funding This work was supported by funds from the National Natural Science Foundation for Young Scholars of China (72004151) and the Sichuan Natural Science Foundation Youth Fund Project (23NSFSC4810).
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background Infantile epileptic spasms syndrome (IESS) is the most common epileptic encephalopathy in infancy and early childhood. At present, adrenocorticotropic hormone (ACTH) and prednisolone are commonly used as drug treatment regimens for IESS. However, evidence of efficacy and economics remains controversial. This study aimed to evaluate the effectiveness, safety, and economy of ACTH and prednisolone of IESS.

Methods Seven literature databases and two clinical trial registration platforms were searched, and a meta-analysis was conducted. From the perspective of the health care system, a 14-day economic evaluation was conducted. The rate of spasm cessation on the 14th day was used as the effect index. The univariate sensitivity analysis was used to verify the robustness of the results.

Results Nine randomized controlled trials (RCTs) were included. Current clinical evidence is not sufficient to prove the difference in the rate of spasm cessation on the 14th day (risk ratio [RR] = 1.05, 95% CI 0.86–1.27, p = 0.64) and total adverse event rate (RR = 0.87, 95% CI 0.53–1.42, p = 0.57). ACTH had an advantage in improving electroclinical response on the 14th day (RR = 1.46, 95% CI 1.09–1.96, p = 0.01) and reducing the number of months taken for relapse (mean difference = 1.65, 95% CI 1.01–2.29, p < 0.01). The cost of ACTH and prednisolone was 5,629.19 yuan and 5.56 yuan, respectively. Univariate sensitivity analysis showed the most influential factor was the cost of ACTH.

Conclusions There is insufficient evidence to determine whether ACTH or prednisolone is better in the short-term regimen of IESS. ACTH may have more advantages in improving the long-term outcome of IESS. In China, a prednisolone regimen of IESS has a lower cost within 14 days.

Keywords

infantile epileptic spasms syndrome - adrenocorticotropic hormone - prednisolone - meta-analysis - cost-minimization analysis

Supplementary Material



Publikationsverlauf

Eingereicht: 27. Oktober 2024

Angenommen: 15. Januar 2025

Artikel online veröffentlicht:
03. Februar 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Zuberi SM, Wirrell E, Yozawitz E. et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63 (06) 1349-1397
    CrossrefPubMedSuche in Google Scholar
  • 2 Trevathan E, Murphy CC, Yeargin-Allsopp M. The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia 1999; 40 (06) 748-751
    CrossrefPubMedSuche in Google Scholar
  • 3 Sidenvall R, Eeg-Olofsson O. Epidemiology of infantile spasms in Sweden. Epilepsia 1995; 36 (06) 572-574
    CrossrefPubMedSuche in Google Scholar
  • 4 Lúthvígsson P, Olafsson E, Sigurthardóttir S, Hauser WA. Epidemiologic features of infantile spasms in Iceland. Epilepsia 1994; 35 (04) 802-805
    CrossrefPubMedSuche in Google Scholar
  • 5 Pellock JM, Hrachovy R, Shinnar S. et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010; 51 (10) 2175-2189
    CrossrefPubMedSuche in Google Scholar
  • 6 Appleton RE. West syndrome: long-term prognosis and social aspects. Brain Dev 2001; 23 (07) 688-691
    CrossrefPubMedSuche in Google Scholar
  • 7 Song JM, Hahn J, Kim SH, Chang MJ. Efficacy of treatments for infantile spasms: a systematic review. Clin Neuropharmacol 2017; 40 (02) 63-84
    CrossrefPubMedSuche in Google Scholar
  • 8 Go CY, Mackay MT, Weiss SK. et al; Child Neurology Society, American Academy of Neurology. Evidence-based guideline update: medical treatment of infantile spasms. Neurology 2012; 78 (24) 1974-1980
    CrossrefPubMedSuche in Google Scholar
  • 9 Wilmshurst JM, Gaillard WD, Vinayan KP. et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia 2015; 56 (08) 1185-1197
    CrossrefPubMedSuche in Google Scholar
  • 10 Hrachovy RA, Frost Jr JD, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr 1983; 103 (04) 641-645
    CrossrefPubMedSuche in Google Scholar
  • 11 Kusse MC, van Nieuwenhuizen O, van Huffelen AC, van der Mey W, Thijssen JH, van Ree JM. The effect of non-depot ACTH(1-24) on infantile spasms. Dev Med Child Neurol 1993; 35 (12) 1067-1073
    CrossrefPubMedSuche in Google Scholar
  • 12 Eidlitz-Markus T, Kivity S, Goldberg-Stern H, Haimi-Cohen Y, Zeharia A. Effect of high-dose glucocorticosteroid treatment for infantile spasms on quantitative bone parameters later in life. J Child Neurol 2012; 27 (01) 74-79
    CrossrefPubMedSuche in Google Scholar
  • 13 Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms. J Child Neurol 2007; 22 (12) 1360-1366
    CrossrefPubMedSuche in Google Scholar
  • 14 Doré-Brabant G, Laflamme G, Millette M, Osterman B, Chrestian N. Adrenal insufficiency among children treated with hormonal therapy for infantile spasms. Epilepsia 2022; 63 (09) 2350-2358
    CrossrefPubMedSuche in Google Scholar
  • 15 McGarry L, Messer R, Cree-Green M, Ray K, Knupp K. Incidence of hypertension among children treated with adrenocorticotropic hormone (ACTH) or prednisolone for infantile spasms. J Child Neurol 2020; 35 (03) 215-220
    CrossrefPubMedSuche in Google Scholar
  • 16 O'Callaghan FJK, Edwards SW, Alber FD. et al; Participating Investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017; 16 (01) 33-42
    CrossrefPubMedSuche in Google Scholar
  • 17 Lux AL, Edwards SW, Hancock E. et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364 (9447) 1773-1778
    CrossrefPubMedSuche in Google Scholar
  • 18 Wanigasinghe J, Arambepola C, Sri Ranganathan S, Sumanasena S, Muhandiram EC. The efficacy of moderate-to-high dose oral prednisolone versus low-to-moderate dose intramuscular corticotropin for improvement of hypsarrhythmia in West syndrome: a randomized, single-blind, parallel clinical trial. Pediatr Neurol 2014; 51 (01) 24-30
    CrossrefPubMedSuche in Google Scholar
  • 19 Jiang ZP, Peng Q, Luo D, Yuan YH. Clinical comparison between prednisolone and adrenocorticotropic hormone in the treatment of infantile spasms. Shiyong Yaowu Yu Linchuang 2019; 22 (06) 634-637
    PubMedSuche in Google Scholar
  • 20 Ai LL, Yuan J, Li LX. Observations on the effectiveness and safety of adrenocorticotropic hormone in the treatment of infantile spasms. Home Med 2020; (07) 98-99
    PubMedSuche in Google Scholar
  • 21 Chen H, Zhong JM, Yi ZS, Zha J, Chen Y, Cai LY. The efficacy of prednisolone in the treatment of infantile spasm and HPA axis mechanism analysis. Int J Pediatr 2017; 44 (10) 701-706
    PubMedSuche in Google Scholar
  • 22 Wang XY, Han ZM, Zhang FM, Han MG, Huang Q. Progress in the study of the inhibitory effect of glucocorticoids on the adrenal cortex. Journal of Xinxiang Medical University 2021; 38 (01) 97-100 , 105
    PubMedSuche in Google Scholar
  • 23 Wang YJ, Zou LP. Infantile spasms and the adrenocorticotropin-releasing hormone hypothesis. J Pract Med 2011; 27 (24) 4504-4505
    PubMedSuche in Google Scholar
  • 24 Chen H, Zhong JM, Yi ZS, Zha J, Chen Y, Cai LY. [Immunological mechanism of prednisone in the treatment of infantile spasm]. Zhongguo Dang Dai Er Ke Za Zhi 2017; 19 (10) 1044-1050
    PubMedSuche in Google Scholar
  • 25 Hrachovy RA, Frost Jr JD. Infantile spasms. Handb Clin Neurol 2013; 111: 611-618
    CrossrefPubMedSuche in Google Scholar
  • 26 Glaze DG, Hrachovy RA, Frost Jr JD, Kellaway P, Zion TE. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatr 1988; 112 (03) 389-396
    CrossrefPubMedSuche in Google Scholar
  • 27 Riikonen R. A long-term follow-up study of 214 children with the syndrome of infantile spasms. Neuropediatrics 1982; 13 (01) 14-23
    Thieme ConnectPubMedSuche in Google Scholar
  • 28 Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 1999; 40 (03) 286-289
    CrossrefPubMedSuche in Google Scholar
  • 29 Riikonen R. Infantile spasms: outcome in clinical studies. Pediatr Neurol 2020; 108: 54-64
    CrossrefPubMedSuche in Google Scholar
  • 30 Ji XN, Chen Q. Advances in the diagnosis and treatment of infantile spasms. Chinese Clinical Doctor. 2020; 48 (07) 771-776
    PubMedSuche in Google Scholar
  • 31 Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2013; 2013 (06) CD001770
    PubMedSuche in Google Scholar
  • 32 Chen M, Liu XM. Efficacy of short-term ACTH pulse sequential prednisolone in the treatment of infantile spasms and its influence on electroencephalogram. J Brain Nervous Dis 2022; 30 (03) 133-137
    PubMedSuche in Google Scholar
  • 33 Cao XY, Cao DZ. Genetic etiology of West syndrome and related therapeutic advances. Chin J Nervous Ment Dis 2021; 47 (04) 242-246
    PubMedSuche in Google Scholar
  • 34 Wray CD, Benke TA. Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms. Pediatr Neurol 2010; 43 (03) 163-166
    CrossrefPubMedSuche in Google Scholar
  • 35 Imannezhad S, Akhondian J, Ashrafzadeh F. et al. A single-center randomized clinical trial comparing the treatment efficacy of high dose oral prednisolone with intramuscular adrenocorticotropic hormone in patients with infantile spasm. Int J Pediatr (Mashhad) 2020; 8 (10) 12157-12163
    PubMedSuche in Google Scholar
  • 36 Gowda VK, Narayanaswamy V, Shivappa SK, Benakappa N, Benakappa A. Corticotrophin-ACTH in comparison to prednisolone in West Syndrome - a randomized study. Indian J Pediatr 2019; 86 (02) 165-170
    CrossrefPubMedSuche in Google Scholar
  • 37 Wanigasinghe J, Arambepola C, Sri Ranganathan S, Sumanasena S, Attanapola G. Randomized, single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular corticotropin on immediate and continued spasm control in West Syndrome. Pediatr Neurol 2015; 53 (03) 193-199
    CrossrefPubMedSuche in Google Scholar
  • 38 Wanigasinghe J, Arambepola C, Ranganathan SS, Sumanasena S. Randomized, single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular corticotropin: a 12-month assessment of spasm control in West Syndrome. Pediatr Neurol 2017; 76: 14-19
    CrossrefPubMedSuche in Google Scholar
  • 39 Lux AL, Edwards SW, Hancock E. et al; United Kingdom Infantile Spasms Study. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4 (11) 712-717
    CrossrefPubMedSuche in Google Scholar
  • 40 Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996; 97 (03) 375-379
    CrossrefPubMedSuche in Google Scholar